Light and Shadow of Na-Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Points for Improvement Based on Our Clinical Experience

Figure 2

(a) Change in HbA1c from six months to two years. For each of the 236 patients, we calculated the difference between the HbA1c at six months and two years after the start of treatment, and the histogram showed the mean difference (difference-HbA1c). 41.5% of the patients tended to improve, and 58.5% tended to worsen. Only 14.5% of the patients improved by 1.0% or more. (b) Rate of change (⊿%) in HbA1c between the groups whose HbA1c levels ameliorated and worsened from six months to two years after the start of treatment (two-way repeated analysis of variance). Ameliorating group: patients whose HbA1c level decreased by 1.0% or more. Worsening group: patients whose HbA1c level increased by 1.0% or more.

(a)

(b)